July 1 2016: Dyne Immune Institute Joins the Medical CBRN Defense Consortium (MCDC)
Dyne Immune Institute for Translation Medicine and Research has joined The Medical CBRN Defense Consortium (MCDC), a newly formed group focused on advancing development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. It was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with industry, academia, and not-for-profit partners. The intent is to:
- Afford greater visibility into Government needs and priorities; provides increased ability to leverage IR&D investments to meet those needs
- Create a channel for small companies and non-traditional suppliers to identify opportunities and establish customer relationships
- Operate through a flexible contracting vehicle capable of multiple tasking with a single set of terms and conditions
The envisioned collaboration focuses on supporting the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) and their seven Joint Program Management (JPM) Offices to counter Chemical Biological Radiological and Nuclear (CBRN) threats. With the following near term objectives:
Prevent
Prophylaxis, pretreatment, and post-exposure prophylaxis.
Diagnose
Systems and devices to identify CBRN agents and assist in making medical decisions.
Treat
Therapeutics for post-exposure and post-symptomatic.
Dyne Immune Institute, Medical Countermeasures System, objective is to provide MCDC advanced early detection field assay, prophylactic and vaccine technology to protect US military forces and the nation.
|
